Evidence map›Paper›PMID 42803812›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026

Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies.

Buthina A Al-Oudat, Farah B Al-Omari, Suaad A Audat, Nizar A Al-Shar'i, Qosay A Al-Balas

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Buthina A Al-OudatDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan. baoudat@just.edu.jo.
Farah B Al-OmariDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
Suaad A AudatDepartment of Chemistry, Faculty of Science and Arts, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
Nizar A Al-Shar'iDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Qosay A Al-BalasDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.

Funding

Deanship of Research at the Jordan University of Science and Technology Grant No. 20220524
6 · The paper itself

Abstract

Glyoxalase I (Glo-I) enzyme is a validated anticancer target due to its role in methylglyoxal detoxification and its association with tumor progression and drug resistance. Inhibition of Glo-I promotes the accumulation of toxic metabolites and can trigger apoptosis in cancer cells. Building on our previously reported bis-imine Glo-I inhibitor N3 (IC

Indexed as

Glyoxalase I enzymeGlyoxalase I inhibitorsHydroxylated bis-imine derivativesMolecular docking

Identifiers

PMID42803812

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.